Aspirin-intolerant asthma in the population: Prevalence and important determinants

Clinical and Experimental Allergy

Volumn 45, Issue 1, 2015, Pages 211-219

  Eriksson, J ^a   Ekerljung, L ^a   Bossios, A ^a   Bjerg, A ^a   Wennergren, G ^a   Ronmark E ^b,c   Toren K ^a   Lotvall J ^a   Lundback B ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SUNDERBY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

Aspirin intolerant asthma; Epidemiology; Obesity; Population survey; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; AIR POLLUTANT;

ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTICLE; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; BODY MASS; CHRONIC RHINOSINUSITIS; CONTROLLED STUDY; DOSE RESPONSE; DYSPNEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MORBIDITY; MOULD; OBESITY; OCCUPATIONAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SENSITIZATION; SMOKING; SWEDEN; ADVERSE EFFECTS; AIR POLLUTANT; ASTHMA, ASPIRIN-INDUCED; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; QUESTIONNAIRE; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AIR POLLUTANTS; ASTHMA, ASPIRIN-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OCCUPATIONAL EXPOSURE; PREVALENCE; QUESTIONNAIRES; RISK FACTORS; SEX FACTORS; SMOKING; SWEDEN;

EID: 84919766645     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12359     Document Type: Article

References (39)

1. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med 2006; 355:2226-35.
2. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368:804-13.
3. Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol 2013; 131:627-34.
4. Lötvall J, Akdis CA, Bacharier LB et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127:355-60.
5. Sanak M, Gielicz A, Bochenek G, Kaszuba M, Nizankowska-Mogilnicka E, Szczeklik A. Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. J Allergy Clin Immunol 2011; 127:1141-7.
6. Widal M, Abrami P, Lermeyez J. Anaphylaxie et idiosyncrasie. Presse Med 1922; 30:189-93.
7. Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68:975-83.
8. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328:434.
9. Kasper L, Sladek K, Duplaga M et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 2003; 58:1064-6.
10. Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002; 57:569-74.
11. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999; 28:717-22.
12. Rönmark E, Andersson C, Nyström L, Forsberg B, Järvholm B, Lundbäck B. Obesity increases the risk of incident asthma among adults. Eur Respir J 2005; 25:282-8.
13. Ford ES. The epidemiology of obesity and asthma. J Allergy Clin Immunol 2005; 115:897-909.
14. Wenzel SE, Busse WW. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119:14-21.
15. Mosen DM, Schatz M, Magid DJ, Camargo CA Jr. The relationship between obesity and asthma severity and control in adults. J Allergy Clin Immunol 2008; 122:507-11.
16. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16:432-6.
17. Fukutomi Y, Nakamura H, Kobayashi F et al. Nationwide cross-sectional population-based study on the prevalences of asthma and asthma symptoms among Japanese adults. Int Arch Allergy Immunol 2010; 153:280-7.
18. Lötvall J, Ekerljung L, Rönmark EP et al. West Sweden Asthma Study: prevalence trends over the last 18 years argues no recent increase in asthma. Respir Res 2009; 10:94.
19. Rönmark EP, Ekerljung L, Lötvall J, Torén K, Rönmark E, Lundbäck B. Large scale questionnaire survey on respiratory health in Sweden: effects of late- and non-response. Respir Med 2009; 103:1807-15.
20. Ekerljung L, Bossios A, Lötvall J et al. Multi-symptom asthma as an indication of disease severity in epidemiology. Eur Respir J 2011; 38:825-32.
21. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J 2003; 22:470-7.
22. Jang AS, Park JS, Park SW et al. Obesity in aspirin-tolerant and aspirin-intolerant asthmatics. Respirology 2008; 13:1034-8.
23. Kim DM, Ahn CW, Nam SY. Prevalence of obesity in Korea. Obes Rev 2005; 6:117-21.
24. Neovius M, Janson A, Rössner S. Prevalence of obesity in Sweden. Obes Rev 2006; 7:1-3.
25. Corrigan CJ, Napoli RL, Meng Q et al. Reduced expression of the prostaglandin E2 receptor E-prostanoid 2 on bronchial mucosal leukocytes in patients with aspirin-sensitive asthma. J Allergy Clin Immunol 2012; 129:1636-46.
26. Choi SJ, Ye YM, Hur GY, Shin SY, Han JH, Park HS. Neutrophil activation in patients with ASA-induced urticaria. J Clin Immunol 2008; 28:244-9.
27. Shore SA. Obesity and asthma: possible mechanisms. J Allergy Clin Immunol 2008; 121:1087-93.
28. Beuther DA, Weiss ST, Sutherland ER. Obesity and asthma. Am J Respir Crit Care Med 2006; 174:112-9.
29. Kavazarakis E, Moustaki M, Gourgiotis D et al. Relation of serum leptin levels to lipid profile in healthy children. Metabolism 2001; 50:1091-4.
30. Shore SA, Schwartzman IN, Mellema MS, Flynt L, Imrich A, Johnston RA. Effect of leptin on allergic airway responses in mice. J Allergy Clin Immunol 2005; 115:103-9.
31. Lugogo NL, Kraft M, Dixon AE. Does obesity produce a distinct asthma phenotype? J Appl Physiol 2010; 108:729-34.
32. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003; 111:913-21.
33. Cederholm T, Lindgren JA, Palmblad J. Impaired leukotriene C4 generation in granulocytes from protein-energy malnourished chronically ill elderly. J Intern Med 2000; 247:715-22.
34. Giouleka P, Papatheodorou G, Lyberopoulos P et al. Body mass index is associated with leukotriene inflammation in asthmatics. Eur J Clin Invest 2011; 41:30-8.
35. Bochenek G, Nizankowska E, Szczeklik A. The atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 1996; 51:16-23.
36. Peden DB, Bush RK. Advances in environmental and occupational disorders in 2012. J Allergy Clin Immunol 2013; 131:668-74.
37. Chang JE, Ding D, Martin-Lazaro J, White A, Stevenson DD. Smoking, environmental tobacco smoke, and aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2012; 108:14-9.
38. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005; 116:970-5.
39. Chang HS, Park JS, Jang AS et al. Diagnostic value of clinical parameters in the prediction of aspirin-exacerbated respiratory disease in asthma. Allergy Asthma Immunol Res 2011; 3:256-64.